Agenus Inc. develops immuno-oncology therapies for cancer, with recurring updates centered on botensilimab (BOT) and balstilimab (BAL), its CTLA-4/PD-1 immunotherapy combination. Company news regularly covers clinical data in solid tumors, including metastatic colorectal cancer, melanoma and gastroesophageal cancer, as well as translational biomarker work and combination approaches that use antibody therapeutics, adoptive cell therapy through MiNK Therapeutics and adjuvants.
Agenus updates also address regulatory-authorized access pathways for BOT+BAL, including France's AAC framework and paid named-patient programs where permitted, along with financial results, equity financing activity, commercial readiness, manufacturing collaborations and corporate governance developments.
Agenus (NASDAQ: AGEN), a clinical-stage immuno-oncology company, announced that Dr. Garo Armen, Chairman and CEO, along with Dr. Steven O’Day, Chief Medical Officer, will present at two upcoming investor conferences. The Guggenheim 5th Annual Oncology Day will feature a fireside chat on February 9, 2023, at 9:35 AM ET, while the SVB Securities Global Biopharma Conference will host a virtual fireside chat on February 16, 2023, at 10:00 AM ET. Interested parties can access live webcasts through the company’s website. Agenus focuses on cancer immunotherapy, leveraging various therapeutic approaches and resources.
Agenus reported promising clinical data from a Phase 1b study of botensilimab combined with balstilimab in treating microsatellite stable colorectal cancer (MSS CRC). In an expanded cohort of 70 heavily pre-treated patients, the overall response rate (ORR) was 23%, while the disease control rate (DCR) was 76%. Remarkably, 69% of responses were ongoing at the data cut-off, and median overall survival has not yet been reached. The company plans to initiate a Phase 3 trial for MSS CRC in 2023, underscoring a commitment to address the significant unmet needs in this patient population.
Agenus (NASDAQ: AGEN), an immuno-oncology firm, announced participation by Chairman and CEO Dr. Garo Armen and Chief Medical Officer Dr. Steven O’Day in a virtual fireside chat at the B Riley Securities’ 2023 Virtual Oncology Conference on January 18th at 11:30 am ET. This event offers insights into Agenus's innovative therapies targeting cancer and infections. Interested participants can register for the webcast at B Riley's website. An archived version will be available later on Agenus's Investor page, providing ongoing updates about the company's developments.
Agenus Inc. (NASDAQ: AGEN) announced it will present expanded data on botensilimab, an anti-CTLA-4, in combination with balstilimab, an anti-PD-1, at the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium (ASCO-GI) from January 19-21, 2023, in San Francisco, CA. The presentation will focus on data from the microsatellite stable colorectal cancer cohort of its Phase 1 study and occurs on January 21, 2023, at 10:00am ET. Abstract details, including the presenting author, will be released on January 17, 2023.
Agenus (Nasdaq: AGEN) reported promising results from its Phase 1 study of botensilimab and balstilimab for advanced sarcoma treatment. The study revealed a 46% overall response rate and a 69% disease control rate in heavily pre-treated patients. Notably, responses were observed in historically resistant sarcoma subtypes, including visceral angiosarcoma. Furthermore, 67% of responses lasted over a year. With a 12-month overall survival rate of 77%, Agenus plans further Phase 2 trials in 2023.
Agenus (NASDAQ: AGEN), a leader in immuno-oncology, will participate in the 5th Annual Evercore ISI HealthCONx Conference. Dr. Garo Armen and Dr. Steven O'Day will join a virtual fireside chat on November 30th at 12:35 PM ET. The conference runs from November 29th to December 1st, including one-on-one investor meetings. Interested attendees can register for the webcast, which will also be archived on Agenus' investor website following the event. Agenus focuses on therapies that harness the immune system to combat cancer and infections.
Agenus (Nasdaq: AGEN) reported promising results from its Phase 1 study of botensilimab and balstilimab for treating treatment-resistant tumors, including MSS-CRC, ovarian, and NSCLC. The response rates ranged from 22% in MSS-CRC to 60% in anti-PD-(L)1 resistant NSCLC. The company has initiated Phase 2 ACTIVATE trials for botensilimab in advanced MSS-CRC and melanoma, with pancreatic cancer trials expected by year-end. The therapy has shown higher efficacy and tolerability compared to existing treatments, marking a significant step forward in immuno-oncology.
Agenus Inc. (NASDAQ: AGEN) provided a corporate update and third-quarter 2022 financial results, highlighting the promising Phase 1 study of botensilimab, an anti-CTLA-4 therapy. The company initiated Phase 2 ACTIVATE trials for botensilimab in advanced colorectal cancer and melanoma. The firm ended Q3 with $218 million in cash and reported a net loss of $56.7 million, or $0.19 per share. Revenue for the quarter was $22.8 million, down significantly from the previous year. Agenus plans to present expanded data at the SITC Annual Meeting on November 12.
Agenus (NASDAQ: AGEN) announced it will release its Q2 2022 financial results before the market opens on November 8, 2022. The company will host a conference call at 8:30 a.m. ET to discuss the results and provide updates. On November 12, 2022, Agenus will hold an R&D event titled “The Road Taken” in Boston, featuring insights from oncology experts regarding botensilimab and its development in cold tumors. Investors may access the conference call and R&D event via dial-in and webcast, respectively.
Agenus Inc. has reported positive results from GSK's pivotal Phase III trial of its RSV vaccine for adults over 60, achieving an overall efficacy of 82.6% against RSV lower respiratory tract disease (RSV-LRTD). Notably, the vaccine demonstrated 94.1% efficacy against severe disease and high efficacy rates in those aged 70-79 and with comorbidities. Regulatory filings are expected in the second half of 2022, potentially leading to the approval of one of three vaccines utilizing Agenus' proprietary QS-21 STIMULON adjuvant.